A Phase 3 interventional study of Secukinumab in Moderate to Severe Plaque-type Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 89 sites in Germany. Per ClinicalTrials.gov, last updated 2019-07-05.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing secukinumab in Skin Diseases — none open to participants now, none under way, none of them phase 3. secukinumab · Skin Diseases.
Among the 10 studies testing secukinumab in Skin Diseases, this one has the largest enrollment, is one of 2 that started in 2015, is one of 7 in phase 3, and was the 7th registered.
497 studies on the registry are indexed under Skin Diseases; 78 are open to participants now.
Browse Skin Diseases studies →None of the 10 studies testing secukinumab in Skin Diseases is open now. The open studies under Skin Diseases, anywhere →
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Skin Diseases studies recruiting now, 27 (49%) set no upper age limit and 18 (33%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2015.
This study's enrollment of 772 is above the median of 70 across 375 interventional studies indexed under Skin Diseases.
Median enrollment 156 across the 10 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 2 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
16 studies in Skin Diseases by Novartis: none open now, none under way, none of them phase 3. Of 14 finished, 13 (93%) have results posted.
Among the 16 studies in Skin Diseases by Novartis, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2015, is one of 7 in phase 3, and was the 10th registered.
Novartis’s Skin Diseases studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing secukinumab in Skin Diseases, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 16 in Skin Diseases:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to support the optimal use of secukinumab by providing data to refine guidance on dosing flexibility in patients with psoriasis. The purpose of the study is to explore the effects of dosage interval shorteng to achieve PASI 90 at week 32 for patients who had less than almost clear skin at week 16.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects eligible for inclusion in this study must fulfill all of the following criteria:
Exclusion Criteria:
Women who are pregnant or breast feeding (pregnancy defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/ml)) who are menstruating and capable of becoming pregnant* and not practicing a medically approved method of (Pearl Index \<1**) during and up to at least 4 weeks after the end of treatment. A negative pregnancy test (serum) for all women and for girls entering menarche is required with sufficient lead time before inclusion
*definition of : 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/m or 6 weeks post- surgical bilateral oophorectomy with or without hysterectomy
**examples of particularly reliable methods with Pearl Index (PI) \<1, according to guidelines of Deutsche Gesellschaft für Gynakologie und Geburtshilfe:
No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible subjects.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Secukinumab
Drug: Secukinumab
Number of Participants With PASI 90 Response at Week 32
Number of participants with at least 90% improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
Time frame: at 32 weeks
Number of Participants With PASI 90 Response at Week 32 for PPS
Number of participants with at least 90% improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
Time frame: at week 32
Selection Phase: Number of Participants Achieving (Psoriasis Area and Severity Index Score)PASI 50, 75, 90, 100
Number of participants with at least 50, 75, 90 or 100% improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
Time frame: at weeks 1, 2, 3, 4, 8, 12 and 16
Comparative Dose Phase: Number of Participants Achieving Psoriasis Area and Severity Index Score (PASI) 90 and 100
Number of participants with at least 90 or 100% improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
Time frame: at weeks 18, 22, 30, 32
Selection Phase:Summary of PASI Total Score
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
Time frame: at weeks 1,2,3,4,8, 12, 16
Comparative Dose Phase: Summary of PASI Total Score
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
Time frame: Weeks 18, 22, 26, 30 and 32
Number of Patients Achieving Dermatology Life Quality Index (DLQI) Scores of 0 or 1 by Visits in the CDP
The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. The DLQI was designed to assess health-related quality of life (HRQoL) in adult patients with skin diseases including psoriasis.
Time frame: Weeks 4, 16, 18, 22, 26, 30, 32
Number of Patients Achieving DLQI Total Score <= 5 in the CDP
The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.
Time frame: Weeks 4, 16, 18, 22, 26, 30, 32
Selection Phase: Number of Patients Achieving Investigator Global Assessment (IGA) 0 or 1
The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe.
Time frame: Weeks 4, 16
Comparative Dose Phase: Number of Patients Achieving Investigator Global Assessment (IGA) 0 or 1
The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe.
Time frame: Weeks 18, 22, 26, 30, 32
Selection Phase: Summary of IGA Score
The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe.
Time frame: Weeks 4, 16
Comparative Dose Phase:Summary of IGA Score
The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe.
Time frame: Weeks 18, 22, 26, 30, 32
860 screened (not shown here). In selection phase (SP), 772 received 300 mg s.c. open-label secukinumab at baseline to wk 12. Those who did not achieve ≥Psoriasis Area and Severity Index (PASI) 75 at wk 16 discontinued. Those who had ≤ clear or almost clear skin (≥PASI75 but not PASI90) rolled over into double blind comparative dosing phase (CDP).
| Milestone | SP - Secukinumab 300 mg s.c. (4-weekly) | CDP - Secukinumab 300 mg s.c. (4-weekly) | CDP - Secukinumab 300 mg s.c. (2-weekly) |
|---|---|---|---|
| Started | 772 | 0 | 0 |
| Completed | 749 | 0 | 0 |
| Not completed | 23 | 0 | 0 |
| Withdrew: Adverse event | 8 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: No longer requires treatment | 1 | 0 | 0 |
| Withdrew: Technical problem | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 0 |
| Withdrew: Withdrawal of informed consent | 3 | 0 | 0 |
| Milestone | SP - Secukinumab 300 mg s.c. (4-weekly) | CDP - Secukinumab 300 mg s.c. (4-weekly) | CDP - Secukinumab 300 mg s.c. (2-weekly) |
|---|---|---|---|
| Started | 0 | 162 | 163 |
| Completed | 0 | 153 | 157 |
| Not completed | 0 | 9 | 6 |
| Withdrew: Adverse event | 0 | 3 | 2 |
| Withdrew: Lost to follow-up | 0 | 4 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Withdrawal of informed consent | 0 | 2 | 2 |
Number of participants with at least 90% improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
| participants | CDP - Secukinumab 300 mg s.c. (4-weekly) | CDP - Secukinumab 300 mg s.c. (2-weekly) |
|---|---|---|
| Number of Participants With PASI 90 Response at Week 32 | 93 | 105 |
Number of participants with at least 90% improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
| participants | CDP - Secukinumab 300 mg s.c. (4-weekly) | CDP - Secukinumab 300 mg s.c. (2-weekly) |
|---|---|---|
| Number of Participants With PASI 90 Response at Week 32 for PPS | 81 | 85 |
Number of participants with at least 50, 75, 90 or 100% improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
| Number of participants | SP - Secukinumab 300 mg s.c. (4-weekly) |
|---|---|
| Week 1, PASI 50 | 43 |
| Week 1, PASI 75 | 3 |
| Week 1, PASI 90 | 0 |
| Week 1, PASI 100 | 0 |
| Week 2, PASI 50 | 232 |
| week 2, PASI 75 | 25 |
| Week 2, PASI 90 | 5 |
| Week 2, PASI 100 | 1 |
| Week 3, PASI 50 | 468 |
| Week 3, PASI 75 | 128 |
| Week 3, PASI 90 | 22 |
| Week 3, PASI 100 | 3 |
| Week 4, PASI 50 | 591 |
| Week 4, PASI 75 | 281 |
| Week 4, PASI 90 | 71 |
| Week 4, PASI 100 | 12 |
| Week 8, PASI 50 | 718 |
| Week 8, PASI 75 | 538 |
| Week 8, PASI 90 | 266 |
| Week 8, PASI 100 | 70 |
| Week 12, PASI 50 | 733 |
| Week 12, PASI 75 | 611 |
| Week 12, PASI 90 | 370 |
| Week 12, PASI 100 | 110 |
| Week 16, PASI 50 | 732 |
| Week 16, PASI 75 | 698 |
| Week 16, PASI 90 | 363 |
| Week 16, PASI 100 | 124 |
Number of participants with at least 90 or 100% improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
| Number of participants | CDP - Secukinumab 300 mg s.c. (4-weekly) | CDP - Secukinumab 300 mg s.c. (2-weekly) |
|---|---|---|
| Week 18, PASI 90 | 42 | 36 |
| Week 18, PASI 100 | 1 | 1 |
| Week 22, PASI 90 | 70 | 67 |
| Week 22, PASI 100 | 9 | 9 |
| Week 26, PASI 90 | 85 | 94 |
| Week 26, PASI 100 | 9 | 14 |
| Week 30, PASI 90 | 93 | 104 |
| Week 30, PASI 100 | 17 | 19 |
| Week 32, PASI 90 | 93 | 105 |
| Week 32, PASI 100 | 22 | 26 |
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
| Score on a Scale | SP - Secukinumab 300 mg s.c. (4-weekly) |
|---|---|
| week 1 | 18.78 ± 9.629 |
| week 2 | 14.32 ± 8.435 |
| week 3 | 10.69 ± 7.372 |
| week 4 | 8.12 ± 6.494 |
| week 8 | 4.41 ± 4.544 |
| Week 12 | 3.34 ± 3.833 |
| Week 16 | 2.90 ± 3.816 |
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
| Score on a Scale | CDP - Secukinumab 300 mg s.c. (4-weekly) | CDP - Secukinumab 300 mg s.c. (2-weekly) |
|---|---|---|
| Week 18 | 3.71 ± 2.532 | 3.59 ± 2.595 |
| Week 22 | 3.24 ± 2.947 | 3.07 ± 2.726 |
| Week 26 | 2.85 ± 2.852 | 2.68 ± 3.393 |
| Week 30 | 2.83 ± 3.339 | 2.34 ± 2.812 |
| Week 32 | 2.84 ± 3.552 | 2.11 ± 2.701 |
The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. The DLQI was designed to assess health-related quality of life (HRQoL) in adult patients with skin diseases including psoriasis.
| participants with DLQI score 0/1 | Secukinumab 300 mg s.c. (4-weekly) | CDP - Secukinumab 300 mg s.c. (2-weekly) |
|---|---|---|
| Week 18 | 65 | 58 |
| Week 22 | 70 | 73 |
| Week 26 | 69 | 83 |
| Week 30 | 75 | 89 |
| Week 32 | 82 | 96 |
The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.
| participants | Secukinumab 300 mg s.c. (4-weekly) | CDP - Secukinumab 300 mg s.c. (2-weekly) |
|---|---|---|
| Week 18 | 109 | 108 |
| Week 22 | 112 | 117 |
| Week 26 | 116 | 121 |
| Week 30 | 114 | 127 |
| Week 32 | 117 | 126 |
The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe.
| Participants | SP - Secukinumab 300 mg s.c. (4-weekly) |
|---|---|
| week 4 | 150 |
| week 16 | 446 |
The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe.
| Participants | CDP - Secukinumab 300 mg s.c. (4-weekly) | CDP - Secukinumab 300 mg s.c. (2-weekly) |
|---|---|---|
| week 18 | 67 | 68 |
| week 22 | 88 | 90 |
| week 26 | 87 | 111 |
| week 30 | 97 | 106 |
| week 32 | 98 | 111 |
The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe.
| Score on a scale | SP - Secukinumab 300 mg s.c. (4-weekly) |
|---|---|
| Week 4 | 2.10 ± 0.790 |
| Week 16 | 1.26 ± 0.875 |
The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe.
| Score on a scale | CDP - Secukinumab 300 mg s.c. (4-weekly) | CDP - Secukinumab 300 mg s.c. (2-weekly) |
|---|---|---|
| Week 18 | 1.63 ± 0.619 | 1.64 ± 0.656 |
| Week 22 | 1.46 ± 0.733 | 1.42 ± 0.704 |
| Week 26 | 1.48 ± 0.758 | 1.30 ± 0.759 |
| Week 30 | 1.33 ± 0.848 | 1.27 ± 0.803 |
| Week 32 | 1.30 ± 0.925 | 1.13 ± 0.819 |
Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 1 year and 4 months.. Non-serious events are listed at a 0.0001% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SP-Secukinumab: AIN457 300 mg s.c. (4-weekly) | — | 32/772 (4.1%) | 510/772 (66.1%) |
| CDP-Secukinumab: AIN457 300 mg s.c. (4-weekly) | — | 8/162 (4.9%) | 85/162 (52.5%) |
| CDP-Secukinumab: AIN457 300 mg s.c. (2-weekly) | — | 4/163 (2.5%) | 87/163 (53.4%) |
| Event | SP-Secukinumab: AIN457 300 mg s.c. (4-weekly) | CDP-Secukinumab: AIN457 300 mg s.c. (4-weekly) | CDP-Secukinumab: AIN457 300 mg s.c. (2-weekly) |
|---|---|---|---|
| CHEST PAINGeneral disorders | 0/772 | 1/162 | 0/163 |
| IMPAIRED HEALINGGeneral disorders | 0/772 | 1/162 | 0/163 |
| ERYSIPELASInfections and infestations | 0/772 | 1/162 | 0/163 |
| MASTOIDITISInfections and infestations | 0/772 | 1/162 | 0/163 |
| PYODERMAInfections and infestations | 0/772 | 1/162 | 0/163 |
| SINUSITISInfections and infestations | 0/772 | 1/162 | 0/163 |
| CHEST INJURYInjury, poisoning and procedural complications | 0/772 | 1/162 | 0/163 |
| CONTUSIONInjury, poisoning and procedural complications | 0/772 | 1/162 | 0/163 |
| FALLInjury, poisoning and procedural complications | 0/772 | 1/162 | 0/163 |
| WOUNDInjury, poisoning and procedural complications | 0/772 | 1/162 | 0/163 |
| Event | SP-Secukinumab: AIN457 300 mg s.c. (4-weekly) | CDP-Secukinumab: AIN457 300 mg s.c. (4-weekly) | CDP-Secukinumab: AIN457 300 mg s.c. (2-weekly) |
|---|---|---|---|
| NASOPHARYNGITISInfections and infestations | 168/772 | 23/162 | 27/163 |
| HEADACHENervous system disorders | 60/772 | 5/162 | 5/163 |
| DIARRHOEAGastrointestinal disorders | 34/772 | 3/162 | 1/163 |
| PRURITUSSkin and subcutaneous tissue disorders | 32/772 | 2/162 | 0/163 |
| FATIGUEGeneral disorders | 28/772 | 4/162 | 3/163 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 21/772 | 4/162 | 3/163 |
| FOLLICULITISInfections and infestations | 13/772 | 4/162 | 2/163 |
| ECZEMASkin and subcutaneous tissue disorders | 10/772 | 4/162 | 1/163 |
| SCIATICANervous system disorders | 4/772 | 1/162 | 4/163 |
| HYPERTENSIONVascular disorders | 8/772 | 3/162 | 4/163 |
| Age, Continuous(Years) | SP - Secukinumab 300 mg s.c. (4-weekly |
|---|---|
| Mean | 45.8 ± 13.72 |
| Sex/Gender, Customized(Participants) | SP - Secukinumab 300 mg s.c. (4-weekly |
|---|---|
| Female | 222 |
| Male | 550 |
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from Feb 2015 to primary completion in Sep 2016, 19 months.
Results were first posted in Jul 2019, 2 years 9 months after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Skin Diseases, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 19 months is close to that.
Counting every sponsor, half of 60 studies reached it within 19 months; a quarter within 13 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab